Spots Global Cancer Trial Database for Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
Official Title: An Open-label, Non-randomized, Prospective Trial to Evaluate the Effect of Renal Function Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics in Patients With AML or MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Study ID: NCT05534620
Study Description
Brief Summary: This study aim is to assess, if treosulfan pharmacokinetics are influenced by declined renal function and by race/ethnicity of patients. The study also aims to determine an appropriate safe dose of treosulfan, when patient's renal function is impaired. The participants of this study are undergoing allogenic hematopoietic stem cell transplantation for treatment of acute myeloid leukemia or myelodysplastic syndrome.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Illinois, Chicago, Illinois, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
The Ohio State University, Columbus, Ohio, United States
VCU Massey Cancer Center, Richmond, Virginia, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
